Physicochemical Fingerprinting of Cyclosporine A Ophthalmic Emulsions as a New Approach Methodology for Clinical Tolerability

The clinical tolerability profiles of cyclosporine A (CsA) ophthalmic emulsions differ markedly between anionic (Restasis^®, 0.05% CsA) and cationic (Ikervis^®, 0.1% CsA) formulations, despite delivering the same active compound. Anionic emulsions are more frequently associated with transient blurred vision, whereas cationic emulsions are more frequently associated with instillation-site pain. The mechanistic basis for this divergence has not been clearly defined, and conventional evaluation has relied on animal-based irritation assays or large clinical trials. This Commentary proposes a two-phase physicochemical interpretive framework, aligned with New Approach Methodologies (NAMs) and Integrated Approaches to Testing and Assessment (IATA), in which rotational rheometry is used to characterize early instillation-phase behavior (0-5 min) and gas chromatography-mass spectrometry (GC-MS) is used to characterize sustained post-instillation-phase features (5-30 min). Preliminary observations on Restasis, Ikervis, and a 0.5% carboxymethylcellulose-sodium artificial-tear reference (a nonionic, nonsurfactant, low-nociceptive physicochemical control) are presented as supporting context. Restasis exhibited substantially higher viscosity than Ikervis across all shear rates, whereas Ikervis and the CMC reference showed comparable high-shear viscosity despite markedly different reported tolerability-a viscosity-discomfort dissociation. GC-MS putatively identified a long-chain tertiary amine signal exclusively in Ikervis (retention time ≈13.0 min), which was absent in Restasis and the CMC reference. The proposed framework is hypothesis-generating rather than mechanistically conclusive; it is intended to support future targeted validation studies rather than replace clinical evaluation. GC-MS may serve as a useful complementary fingerprinting tool within NAM/IATA-aligned ophthalmic formulation assessment.